Immunosuppressive Factors Produced by Tumors and Their Effects on the RES

  • Steven Specter
  • Herman Friedman


The suppression of immune responses due to tumors has been the subject of intensive investigation during the past decade or so. This subject has been reviewed in detail by Kamo and Friedman (1977a) and by Stutman (1975). In those reviews, the extensive studies performed in many laboratories concerning the nature and mechanism of immunosuppressive factors and immunosuppres-sion per se have been described. The nature and mechanism of how tumors may affect immune responses, either by directly subverting competence or by inducing suppressive factors or cells, were discussed. The present review focuses on immunosuppressive factors produced by tumors and how they alter the re-ticuloendothelial system function. Such tumor-associated or derived factors impair lymphocyte and/or macrophage activity or may generate suppressor cells that depress other immunologic functions.


Soluble Factor Antibody Formation Ehrlich Ascites Tumor Cell Suppressive Factor Immunosuppressive Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abelev, G. L, 1971, Alpha-fetoprotein in ontogenesis and its association with malignant tumors, Adv. Cancer Res. 14:295, 358.PubMedCrossRefGoogle Scholar
  2. Anderson, S. A., Isakson, P. C., Puré, E., Muirhead, M., Uhr, J. W., and Vitteta, E. S., 1981, Immunosuppression in a murine B cell leukemia (BCl1): Role of an adherent cell in the suppression of primary in vitro antibody responses, J. Immunol. 126:1603.PubMedGoogle Scholar
  3. Bjorkland, B., and Bjorkland, V., 1975, Tissue polypeptide antigen (TPA) and antibodies in human cancer defense responses, J. Reticuloendothelial Soc. 18:2a (Supplement).Google Scholar
  4. Brooks, W. H., Netsky, M. G., Normanseil, D. E., and Horwitz, D. A., 1972, Depressed cell-mediated immunity in patients with primary intracranial tumors: Characterization of a humoral immunosuppressive factor, J. Exp. Med. 136:1631.PubMedCrossRefGoogle Scholar
  5. Buffe, D., and Rimbaut, C., 1975, Alpha2-M-globulin, a hepatic glycoferroprotein: Characterization and clinical significance, Ann. N.Y. Acad. Sci. 259:417.PubMedCrossRefGoogle Scholar
  6. Calderon, J., Williams, R. T., and Unanue, E. R., 1974, An inhibitor of cell proliferation released by cultures of macrophages, Proc. Natl. Acad. Sci. USA 71:4273.PubMedCrossRefGoogle Scholar
  7. Cardella, C. J., Davies, P., and Allison, A. C., 1974, Immune complexes induce selective release of lysosomal hydrolases from macrophages, Nature (London) 247:46.CrossRefGoogle Scholar
  8. Chan, P. L., and Sinclair, N. R. S. C., 1973, Immunosuppressive factors associated with tumors, Adv. Exp. Med. Biol. 29:469.PubMedGoogle Scholar
  9. Cooperband, S. R., Nimberg, R., Schmid, K., and Mannick, J. A., 1976, Humoral immunosuppressive factors, Transplant. Proc. 8:225.PubMedGoogle Scholar
  10. Evans, D. L., Frank, M. K., McKinnon, K. P., and Cerrone, M. C., 1981, Suppression of mitogen-and tumor-cell-induced lymphocyte stimulation by tumor-associated fetal antigens, Cell. Immunol. 57:155.PubMedCrossRefGoogle Scholar
  11. Garrigues, H. J., Romero, P., Hellström, I., and Hellström, K. E., 1981, Adherent cells (macrophages?) in tumor-bearing mice suppress MLC responses, Cell. Immunol. 60:109.PubMedCrossRefGoogle Scholar
  12. Glasgow, A. H., Nimberg, R. B., Menzoian, J. O., Saporoschetz, I., Cooperband, S., Schmid, K., and Mannick, J. A., 1974, Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer, N. Engl. J. Med. 291:1263.PubMedCrossRefGoogle Scholar
  13. Gorczynski, R. M., Kilburn, D. G., Knight, R. A., Norbury, C, Parker, D. C., and Smith, T. B., 1975, Nonspecific and specific immunosuppression in tumour-bearing mice by soluble immune complexes, Nature (London) 254:141.CrossRefGoogle Scholar
  14. Hamilton, J. A., 1981, Regulation of prostaglandin and plasminogen activator production by mouse peritoneal macrophages, J. Reticuloendothelial Soc. 30:115.Google Scholar
  15. Hellström, K. E., and Hellström, I., 1974, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, Adv. Immunol. 18:209.PubMedCrossRefGoogle Scholar
  16. Huget, R. P., Flad, H.-D., and Opitz, H. G., 1977, Suppression of in vitro primary immune response by L1210 cells and their culture supernatants: Evidence for cytotoxic effects, Cell. Immunol. 29:210.PubMedCrossRefGoogle Scholar
  17. Kamo, I., and Friedman, H., 1977a, Immunosuppression and the role of suppressive factors in cancer, Adv. Cancer Res. 25:271.PubMedCrossRefGoogle Scholar
  18. Kamo, I., and Friedman, H., 1977b, Characterization of a dialyzable immunosuppressive factor from mastocytoma culture supernatants, Proc. Soc. Exp. Biol. Med. 156:177.PubMedGoogle Scholar
  19. Kamo, I., Patel, C., Kateley, J. R., and Friedman, H., 1975, Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extract, J. Immunol. 114:1749.PubMedGoogle Scholar
  20. Katzmann, J. A., 1978, Myeloma-induced immunosuppression: A multistep mechanism, J. Immunol. 121:1405.PubMedGoogle Scholar
  21. Kennard, J., and Zolla-Pazner, S., 1980, Origin and function of suppressor macrophages in myeloma,J. Immunol. 124:268.PubMedGoogle Scholar
  22. Klein, E., 1972, Tumour immunology: Escape mechanisms, Ann. Inst. Pasteur 122:593.Google Scholar
  23. Kolb, J.-P., Arrian, S., and Zolla-Pazner, S., 1977, Suppression of the humoral immune response by plasmacytomas: Mediation by adherent mononuclear cells, J. Immunol. 118:702.PubMedGoogle Scholar
  24. Koo, P. H., 1981, Immunostimulatory factors specifically associated with a spontaneously regressing tumor subline of the murine leukemia L1210, J. Immunol. 127:373.PubMedGoogle Scholar
  25. Kotiainen, S., 1975, Blocking antigen-antibody complexes on the T lymphocyte surface identified with defined protein antigens. II. Lymphocyte activation during the in vitro response, Immunology 28:535.Google Scholar
  26. Kotiainen, S., and Mitchison, N. A., 1975, Blocking antigen-antibody complexes on the T-lymphocyte surface identified with defined protein antigens. I. Lymphocyte activation during in vitro incubation before adoptive transfer, Immunology 28:5231.Google Scholar
  27. Levy, J. G., Smith, A. G., and Whitney, R. B., 1976, Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice, Immunology 30:565.PubMedGoogle Scholar
  28. Mclntire, K. R., Waldman, T. A., Moertel, C. G., and Go, V. L. W., 1975, Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract, Cancer Res. 35:991.Google Scholar
  29. Masaki, H., Takatsu, K., Hamaoka, T., and Kitogawa, M., 1972, Immunosuppressive activity of chromatin fraction derived from nuclei of Ehrlich ascites tumor cell, Gann 63:633.PubMedGoogle Scholar
  30. Motoki, H., Kamo, I., Kikuchi, M., Ono, Y., and Ishida, N., 1974, Purification of an immunosuppressive principle derived from Ehrlich carcinoma cells, Gann 65:269.PubMedGoogle Scholar
  31. Nakahara, W., and Fukuoka, F., 1949, Toxohormone: A characteristic toxic substance produced by cancer tissue, Gann 40:45.Google Scholar
  32. Nakamura, M., Ishida, N., and Kamo, I., 1980, Immunosuppressive factors from mastocytoma cells cultured in serum-free medium, J. Natl. Cancer Inst. 65:759.PubMedGoogle Scholar
  33. Nimberg, R. B., Glasgow, A. H., Menzoian, J. O., Constantinian, M. B., Cooperband, S., Mannick, J. A., and Schmid, K., 1975, Isolation of an immunosuppressive peptide fraction from the serum of cancer patients, Cancer Res. 35:1489.PubMedGoogle Scholar
  34. Occhino, J. C., Glasgow, A. H., Cooperband, S. R., Mannick, J. A., and Schmid, K., 1973, Isolation of an immunosuppressive peptide fraction from human plasma, J. Immunol. 110:685.PubMedGoogle Scholar
  35. Oldstone, M. B. A., 1975, Immune complexes in cancer: Demonstration of complexes in mice bearing neuroblastomas, J. Natl. Cancer Inst. 54:223.PubMedGoogle Scholar
  36. Plata, F., and Levy, J. P., 1974, Blocking of syngeneic effector T cells by soluble tumour antigens, Nature (London) 249:271.CrossRefGoogle Scholar
  37. Plescia, O. J., Smith, A. H., and Grinwick, K., 1975, Subversion of immune system by tumor cells and role of prostaglandins, Proc. Natl. Acad. Sci. USA 72:1848.PubMedCrossRefGoogle Scholar
  38. Rao, V. S., Grodzicki, R. L., and Mitchell, M. S., 1979, Specific in vivo inhibition of macrophage receptors for cytophilic antibody by soluble immune complexes, Cancer Res. 39:174.PubMedGoogle Scholar
  39. Rigby, P. G., 1969, The delay of allograft rejection by “tumor” ribonucleic acid, Transplantation 7:142.PubMedCrossRefGoogle Scholar
  40. Sjogren, H. O., Hellström, O., Bansal, S. C., and Hellström, K. E., 1971, Suggestive evidence that the “blocking antibodies” of tumor-bearing individuals may be antigen-antibody complexes, Proc. Natl. Acad. Sci. USA 68:1372.PubMedCrossRefGoogle Scholar
  41. Snyderman, R., and Pike, M. C, 1976, An inhibitor of macrophage chemotaxis produced by neoplasms, Science 192:370.PubMedCrossRefGoogle Scholar
  42. Stout, R. D., and Herzenberg, L. A., 1975, The Fc receptor on thymus-derived lymphocytes. II. Mitogen responsiveness of T lymphocytes bearing the Fc receptor, J. Exp. Med. 142:611.PubMedCrossRefGoogle Scholar
  43. Strausser, H. R., and Rosenstein, M. M., 1980, Immunosuppression as a homeostatic mechanism in disease and aging,Adv. Exp. Med. Biol. 121B:277.Google Scholar
  44. Stutman, O., 1975, Immunodepression and malignancy, Adv. Cancer Res. 22:261.PubMedCrossRefGoogle Scholar
  45. Talmage, D. W., Radovich, J., LeFever, J., and Hemmingsen, H., 1973, The role of auxiliary (not antigen-specific) cells in the production of thymus-dependent mediators: Three universes of preprogrammed clones, Ann. N.Y. Acad. Sei. 207:29.CrossRefGoogle Scholar
  46. Ting, C. C., and Rodrigues, D., 1980, Evaluation of the immunocompetence of macrophages and the generation of T-cell mediated cytotoxic response against allogeneic tumor cells in tumor bearers, Int. J. Cancer 25:243PubMedCrossRefGoogle Scholar
  47. Watanabe, M., 1979, Immunosuppression induced by “toxohormone” from mouse tumor cells in culture, Tohoku J. Exp. Med. 128:233.PubMedCrossRefGoogle Scholar
  48. Werkmeister, J., Zbroja, R., McCarthy, W., and Hersey, P., 1980, Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro, Clin. Exp. Immunol. 40:168.PubMedGoogle Scholar
  49. Whitney, R. B., and Levy, J. G., 1975, Mode of action of immunosuppressive substances in sera of tumor-bearing mice, J. Natl. Cancer Inst. 55:1447.PubMedGoogle Scholar
  50. Witz, I. P., Harness, E., and Pilovski, M. A., 1973, Suppressed plaque and rosette-formation by spleen cells of mice injected with tumor extracts, Adv. Exp. Med. Biol. 29:461.PubMedGoogle Scholar
  51. Wong, A., Mankovitz, R., and Kennedy, J. C, 1974, Immunosuppressive and immunostimulatory factors produced by malignant cells in vitro, Int. J. Cancer 13:530.PubMedCrossRefGoogle Scholar
  52. Yamazaki, H., Nitta, K., and Umezawa, H., 1973, Immunosuppression induced with cell-free fluid of Ehrlich carcinoma ascites and its fractions, Gann 64:83.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • Steven Specter
    • 1
  • Herman Friedman
    • 1
  1. 1.Department of Medical Microbiology and ImmunologyUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations